PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC).
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer
FDA approves a new targeted cancer drug called Krazati for lung and colorectal cancers
The FDA has approved Krazati as a single agent for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least…
FDA approves Krazati, a new targeted drug for lung and colorectal cancers with a specific genetic change after other treatments fail.
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
The FDA approved a new treatment for a type of blood cancer called multiple myeloma
The FDA has approved Elrexfio, a bispecific BCMA-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myelom…
A new FDA-approved treatment helps shrink multiple myeloma in patients who have already tried at least four other therapies.
Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect
A meta-analysis of 9 studies (883 patients) found PD-1/PD-L1 inhibitors for recurrent/metastatic nasopharyngeal carcinoma yielded a median O…
For advanced nasopharyngeal cancer, immune therapy helps 43% stay cancer-free for a year while 80% survive, though side effects affect 90% o…
Photobiomodulation reduces severe oral mucositis (RR 0.46) and pain (RR 0.35) in head and neck cancer patients
Can light therapy ease the brutal mouth sores and pain of head and neck cancer treatment? A review of 30 studies suggests it can
A meta-analysis of 30 RCTs (n=1748) found photobiomodulation significantly reduced the risk of severe oral mucositis (RR 0.46, 95% CI: 0.29-…
A review of 30 studies shows light therapy significantly reduces severe mouth sores and pain for head and neck cancer patients while improvi…
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks
Could a new leukemia drug work better and cause fewer side effects than current treatments?
In the ASC4FIRST trial, asciminib demonstrated superior efficacy vs investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP.
A new leukemia drug helped more patients reach deep disease control with fewer side effects than current standard treatments after two years…
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…
Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status
For cancer patients with a leg blood clot and anemia, does longer treatment work better?
In this prespecified subgroup analysis of the ONCO DVT study, 12 months of edoxaban was superior to 3 months for preventing symptomatic recu…
Cancer patients with leg clots and anemia get better protection against new clots with 12 months of edoxaban compared to just 3 months, with…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…